Drugs / PCV10
PCV10
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT02717494 | Mar 2016 → Nov 2018 | congenital human immunodeficiency virus | Westat | Completed | Missed primary |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT03098628 | Mar 2017 → Jun 2020 | — | Murdoch Childrens Research Institute | Completed | Mixed |
| Phase 2/3 | NCT01953510 | Sep 2013 → Jan 2016 | — | Murdoch Childrens Research Institute | Completed | Mixed |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT02943902 | Jan 2017 → Feb 2019 | meningitis, pneumonia | University of Witwatersrand, South Africa | Completed | Met primary |
| Phase 42 trials | ||||||
| Phase 4 | NCT03489018 | Mar 2019 → Sep 2022 | pneumococcal infection | London School of Hygiene and Tropical Medicine | Completed | Mixed |
| Phase 4 | NCT01028326 | Jan → Sep 2010 | streptococcal pneumonia | KEMRI-Wellcome Trust Collaborative Research Program | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT02961231 Comparator | Oct 2016 → Nov 2020 | streptococcal pneumonia | Nagasaki University | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PCV10 | “Therefore the investigators decided to use PCV10 for the study.” NCT02961231 ↗6“a 0+1 schedule of PCV10 at 12 months of age (Group V)” NCT03098628 ↗ |
| Known as | PHiD-CV | “10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV)” PMID 26083474 ↗ Jun 2015 |
| Known as | Synflorix (PCV10) | “Synflorix (PCV10)” NCT02943902 ↗ |
| Modality | Vaccine | “10-valent pneumococcal conjugate vaccine (PCV10)” NCT01028326 ↗ |
| Route | Intramuscular | “0.5mL intramuscular dose of PCV10” NCT01028326 ↗ |